Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

$15.31 -0.18 (-1.16 %)
(As of 12/12/2017 05:06 AM ET)
Previous Close$15.49
Today's Range$15.25 - $15.64
52-Week Range$13.43 - $19.94
Volume996,000 shs
Average Volume1.30 million shs
Market Capitalization$2.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.44

About Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:IRWD
CUSIP46333X10
Phone+1-617-6217722

Debt

Debt-to-Equity Ratio-22.31%
Current Ratio4.87%
Quick Ratio4.86%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$273.96 million
Price / Sales8.37
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book34.02

Profitability

Trailing EPS($0.96)
Net Income$-81,700,000.00
Net Margins-48.89%
Return on Equity-645.22%
Return on Assets-19.69%

Miscellaneous

Employees674
Outstanding Shares149,760,000

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.07. The biotechnology company earned $86.80 million during the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company's revenue for the quarter was up 31.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.18) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When will Ironwood Pharmaceuticals make its next earnings announcement?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 19th 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?

10 brokers have issued twelve-month target prices for Ironwood Pharmaceuticals' stock. Their forecasts range from $13.00 to $21.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $17.88 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:

  • Peter M. Hecht Ph.D., Chief Executive Officer, Director (Age 53)
  • Gina Consylman, Chief Financial Officer, Senior Vice President (Age 45)
  • Mark G. Currie Ph.D., Senior Vice President, Chief Scientific Officer, President - Research and Development (Age 62)
  • Thomas A. McCourt, Senior Vice President - Marketing and Sales, Chief Commercial Officer (Age 59)
  • Halley E. Gilbert Esq., Senior Vice President, Chief Legal Officer, Secretary (Age 47)
  • Christopher I. Wright M.D. Ph.D., Senior Vice President - Global Development and Chief Development Officer
  • Terrance G. McGuire, Non-Executive Independent Chairman of the Board (Age 61)
  • Andrew Dreyfus, Independent Director (Age 58)
  • Marsha H. Fanucci, Independent Director (Age 63)
  • Julie H. McHugh, Independent Director (Age 52)

Who owns Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (5.30%), Pictet Asset Management Ltd. (1.75%), Sector Gamma AS (1.22%), New York State Common Retirement Fund (0.94%), Rothschild Asset Management Inc. (0.85%) and Artal Group S.A. (0.55%). Company insiders that own Ironwood Pharmaceuticals stock include Edward P Owens, Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht, Thomas A Mccourt and Thomas Graney. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Who sold Ironwood Pharmaceuticals stock? Who is selling Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Macquarie Group Ltd., Private Wealth Partners LLC, Chicago Equity Partners LLC, NJ State Employees Deferred Compensation Plan, Janus Henderson Group PLC, California State Teachers Retirement System and First Trust Advisors LP. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Teachers Retirement System of The State of Kentucky, Artal Group S.A., State of Wisconsin Investment Board, Granahan Investment Management Inc. MA, Rothschild Asset Management Inc., New York State Common Retirement Fund and Russell Investments Group Ltd.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy Ironwood Pharmaceuticals stock?

Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $15.31.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $2.29 billion and generates $273.96 million in revenue each year. The biotechnology company earns $-81,700,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Ironwood Pharmaceuticals employs 674 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 Binney St, CAMBRIDGE, MA 02142-1030, United States. The biotechnology company can be reached via phone at +1-617-6217722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (IRWD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  347 (Vote Underperform)
Total Votes:  611
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ironwood Pharmaceuticals (NASDAQ:IRWD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.332.402.382.54
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $17.40$17.67$17.09$17.73
Price Target Upside: 10.13% upside18.41% upside14.55% upside12.63% upside

Ironwood Pharmaceuticals (NASDAQ:IRWD) Consensus Price Target History

Price Target History for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2017MizuhoDowngradeBuy -> Neutral$20.00 -> $16.00HighView Rating Details
12/4/2017Morgan StanleyReiterated RatingHoldHighView Rating Details
11/27/2017Credit Suisse GroupInitiated CoverageBuy$19.00MediumView Rating Details
8/21/2017CowenSet Price TargetBuy$20.00MediumView Rating Details
7/22/2017Wells Fargo & CompanySet Price TargetBuy$19.00LowView Rating Details
7/21/2017Wood & CompanyDowngradeOverweight -> NeutralLowView Rating Details
7/21/2017J P Morgan Chase & CoReiterated RatingOverweight -> Neutral$20.00 -> $19.00HighView Rating Details
6/16/2017WedbushReiterated RatingNeutral$13.00LowView Rating Details
3/13/2017BTIG ResearchReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
2/22/2017BarclaysReiterated RatingEqual Weight -> Equal Weight$13.00 -> $16.00N/AView Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 -> $14.00N/AView Rating Details
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00N/AView Rating Details
3/21/2016Goldman Sachs GroupInitiated CoverageNeutral$14.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Ironwood Pharmaceuticals (NASDAQ:IRWD) Earnings History and Estimates Chart

Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ IRWD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/19/2018($0.18)N/AView Earnings Details
11/2/2017Q3 2017($0.25)($0.18)$73.59 million$86.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.23)($0.28)$70.00 million$65.10 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.19)($0.33)$69.39 million$52.16 millionViewListenView Earnings Details
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewListenView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.45)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Ironwood Pharmaceuticals (NASDAQ:IRWD) Earnings Estimates

2017 EPS Consensus Estimate: ($0.75)
2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.20)($0.22)
Q2 20172($0.23)($0.21)($0.22)
Q3 20172($0.21)($0.12)($0.17)
Q4 20172($0.19)($0.10)($0.15)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.63%
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/7/2017Peter M HechtCEOSell113,405$15.12$1,714,683.60View SEC Filing  
12/4/2017Julie MchughDirectorSell1,500$16.45$24,675.00View SEC Filing  
11/10/2017Gina ConsylmanCFOSell864$15.20$13,132.80View SEC Filing  
9/5/2017Julie MchughDirectorSell1,500$16.16$24,240.00View SEC Filing  
8/18/2017Gina ConsylmanInsiderSell207$14.34$2,968.38View SEC Filing  
6/22/2017Halley E GilbertInsiderSell35,000$19.75$691,250.00View SEC Filing  
5/15/2017Thomas A MccourtInsiderSell30,000$18.20$546,000.00View SEC Filing  
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.75View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.29View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.00View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.00View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.78View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.00View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.25View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.00View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.00View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.00View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.62View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.50View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.00View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.25View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.00View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.00View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.00View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.13View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ironwood Pharmaceuticals (NASDAQ IRWD) News Headlines

Source:
DateHeadline
Ironwood Pharmaceuticals (IRWD) Rating Lowered to Hold at BidaskClubIronwood Pharmaceuticals (IRWD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 9 at 2:24 PM
Zacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) Will Post Quarterly Sales of $81.30 MillionZacks: Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) Will Post Quarterly Sales of $81.30 Million
www.americanbankingnews.com - December 9 at 4:30 AM
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Sells $1,714,683.60 in StockIronwood Pharmaceuticals, Inc. (IRWD) CEO Sells $1,714,683.60 in Stock
www.americanbankingnews.com - December 8 at 5:30 PM
Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : December 8, 2017Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : December 8, 2017
finance.yahoo.com - December 8 at 3:28 PM
-$0.22 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter-$0.22 Earnings Per Share Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - December 7 at 7:26 PM
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : December 7, 2017Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : December 7, 2017
finance.yahoo.com - December 7 at 9:53 AM
Mizuho Downgrades Ironwood Pharmaceuticals (IRWD) to NeutralMizuho Downgrades Ironwood Pharmaceuticals (IRWD) to Neutral
www.americanbankingnews.com - December 6 at 7:52 AM
Ironwood Pharmaceuticals (IRWD) Stock Rating Reaffirmed by Morgan StanleyIronwood Pharmaceuticals (IRWD) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - December 4 at 11:38 AM
Ironwood Pharma stock jumps 3.5% on positive trials of treatment for type 2 diabetesIronwood Pharma stock jumps 3.5% on positive trials of treatment for type 2 diabetes
finance.yahoo.com - December 4 at 9:28 AM
Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial EffectsIronwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects
finance.yahoo.com - December 4 at 9:28 AM
Todays Research Reports on Trending Tickers: UnitedHealth Group Inc. and Ironwood Pharmaceuticals, Inc.Today's Research Reports on Trending Tickers: UnitedHealth Group Inc. and Ironwood Pharmaceuticals, Inc.
finance.yahoo.com - November 28 at 9:40 AM
Ironwood Pharmaceuticals Strengthens Executive Leadership TeamIronwood Pharmaceuticals Strengthens Executive Leadership Team
finance.yahoo.com - November 28 at 9:40 AM
Could The Street Be Underappreciating The Ironwood Pharma Pipeline?Could The Street Be Underappreciating The Ironwood Pharma Pipeline?
finance.yahoo.com - November 27 at 5:20 PM
Ironwood Pharmaceuticals, Inc. (IRWD) Receives New Coverage from Analysts at Credit Suisse GroupIronwood Pharmaceuticals, Inc. (IRWD) Receives New Coverage from Analysts at Credit Suisse Group
www.americanbankingnews.com - November 27 at 11:00 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Downgraded by ValuEngineIronwood Pharmaceuticals, Inc. (IRWD) Downgraded by ValuEngine
www.americanbankingnews.com - November 26 at 12:56 PM
Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Rating of "Hold" by BrokeragesIronwood Pharmaceuticals, Inc. (IRWD) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 26 at 5:24 AM
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : November 21, 2017Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : November 21, 2017
finance.yahoo.com - November 21 at 8:13 PM
Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $81.30 MillionIronwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $81.30 Million
www.americanbankingnews.com - November 21 at 2:10 AM
Traders Purchase Large Volume of Put Options on Ironwood Pharmaceuticals (IRWD)Traders Purchase Large Volume of Put Options on Ironwood Pharmaceuticals (IRWD)
www.americanbankingnews.com - November 19 at 3:52 AM
Ironwood Pharmaceuticals, Inc. (IRWD) CFO Gina Consylman Sells 864 SharesIronwood Pharmaceuticals, Inc. (IRWD) CFO Gina Consylman Sells 864 Shares
www.americanbankingnews.com - November 14 at 10:14 PM
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : November 6, 2017Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : November 6, 2017
finance.yahoo.com - November 7 at 4:55 AM
FY2019 EPS Estimates for Ironwood Pharmaceuticals, Inc. (IRWD) Reduced by WedbushFY2019 EPS Estimates for Ironwood Pharmaceuticals, Inc. (IRWD) Reduced by Wedbush
www.americanbankingnews.com - November 6 at 2:20 PM
Ironwood reports 3Q lossIronwood reports 3Q loss
finance.yahoo.com - November 4 at 2:47 AM
Edited Transcript of IRWD earnings conference call or presentation 2-Nov-17 12:30pm GMTEdited Transcript of IRWD earnings conference call or presentation 2-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 2:47 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Releases  Earnings Results, Beats Expectations By $0.07 EPSIronwood Pharmaceuticals, Inc. (IRWD) Releases Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - November 2 at 3:06 PM
Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare ConferenceIronwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference
finance.yahoo.com - November 2 at 2:47 AM
$68.04 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter$68.04 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - November 1 at 12:20 PM
Ironwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of "Hold" from AnalystsIronwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 1 at 5:48 AM
Sucampos Walls Are Beginning To Close InSucampo's Walls Are Beginning To Close In
seekingalpha.com - October 31 at 4:08 AM
Ironwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual MeetingIronwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual Meeting
finance.yahoo.com - October 30 at 11:07 PM
 Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Earnings of -$0.23 Per Share Analysts Expect Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - October 30 at 9:18 AM
Comparing Blueprint Medicines Corporation (BPMC) and Ironwood Pharmaceuticals (IRWD)Comparing Blueprint Medicines Corporation (BPMC) and Ironwood Pharmaceuticals (IRWD)
www.americanbankingnews.com - October 26 at 9:20 PM
Ironwood Pharmaceuticals, Inc. (IRWD) Scheduled to Post Earnings on WednesdayIronwood Pharmaceuticals, Inc. (IRWD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 5:24 AM
Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update CallIronwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call
finance.yahoo.com - October 20 at 12:48 AM
Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017
finance.yahoo.com - October 16 at 7:29 PM
ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 16, 2017ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 7:29 PM
Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : October 16, 2017Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : October 16, 2017
finance.yahoo.com - October 16 at 7:29 PM
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : October 13, 2017Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : October 13, 2017
finance.yahoo.com - October 13 at 7:50 PM
 Analysts Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Quarterly Sales of $68.04 Million Analysts Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Quarterly Sales of $68.04 Million
www.americanbankingnews.com - October 13 at 5:52 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Receives Average Recommendation of "Hold" from BrokeragesIronwood Pharmaceuticals, Inc. (IRWD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 7 at 7:36 AM
IRWD Makes Bullish Cross Above Critical Moving AverageIRWD Makes Bullish Cross Above Critical Moving Average
www.nasdaq.com - October 7 at 5:00 AM
ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 3, 2017ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 3, 2017
finance.yahoo.com - October 5 at 6:43 AM
Ironwood Pharmaceuticals Struggles With Slump In Sales, Net LossesIronwood Pharmaceuticals Struggles With Slump In Sales, Net Losses
seekingalpha.com - September 26 at 5:04 PM
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : September 26, 2017Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : September 26, 2017
finance.yahoo.com - September 26 at 10:19 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $68.04 MillionIronwood Pharmaceuticals, Inc. (IRWD) Expected to Announce Quarterly Sales of $68.04 Million
www.americanbankingnews.com - September 24 at 1:48 AM
-$0.23 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter-$0.23 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - September 22 at 6:22 PM
ETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017ETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017
finance.yahoo.com - September 14 at 6:33 AM
Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by BrokeragesIronwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 12 at 6:56 AM
TiGenix strengthens US operations with senior appointmentsTiGenix strengthens US operations with senior appointments
feeds.benzinga.com - September 12 at 1:34 AM
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 11 at 8:42 PM

SEC Filings

Ironwood Pharmaceuticals (NASDAQ:IRWD) SEC Filings

DateFilerForm TypeView
12/11/2017
5:01 PM
Currie Mark G (Reporting)
Ironwood Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/08/2017
4:00 PM
Hecht Peter M (Reporting)
Ironwood Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/06/2017
3:14 PM
Ironwood Pharmaceuticals (Issuer)
OLANOFF LAWRENCE S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/06/2017
3:12 PM
Ironwood Pharmaceuticals (Issuer)
McHugh Julie (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Ironwood Pharmaceuticals (NASDAQ:IRWD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ironwood Pharmaceuticals (NASDAQ IRWD) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.